At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
EVAX Evaxion Biotech A/S
Market Closed 05-17 16:00:00 EDT
3.72
-0.11
-2.87%
High3.82Low3.72Vol6.76K
Open3.80D1 Closing3.83Amplitude2.69%
Mkt Cap20.13MTradable Cap14.17MTotal Shares5.41M
T/O25.43KT/O Rate0.18%Tradable Shares3.81M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Evaxion Biotech Faces Nasdaq Compliance Challenge
TIPRANKS  ·  05-11
Evaxion Biotech Faces Nasdaq Compliance Challenge
Evaxion receives Nasdaq notification over minimum stockholders’ equity requirement
seekingalpha  ·  05-11
Evaxion receives Nasdaq notification over minimum stockholders’ equity requirement
Evaxion Receives Nasdaq Notification
GlobeNewswire  ·  05-10
Evaxion Receives Nasdaq Notification
Sidoti Events, LLC's Virtual May Micro-Cap Conference
ACCESSWIRE  ·  05-07
Sidoti Events, LLC's Virtual May Micro-Cap Conference
BRIEF-Evaxion Biotech A/S Files For Offering Of Up To 19.45 Mln Ordinary Shares By Selling Shareholders
Reuters  ·  05-07
BRIEF-Evaxion Biotech A/S Files For Offering Of Up To 19.45 Mln Ordinary Shares By Selling Shareholders
Evaxion Biotech’s Strategic Financial Plans
TIPRANKS  ·  04-26
Evaxion Biotech’s Strategic Financial Plans
Evaxion Biotech Advances Personalized Cancer Vaccine
TIPRANKS  ·  04-17
Evaxion Biotech Advances Personalized Cancer Vaccine
BRIEF-Evaxion Announces Phase 2 Clinical Trial Update
Reuters  ·  04-17
BRIEF-Evaxion Announces Phase 2 Clinical Trial Update
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Zacks  ·  04-03
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Genprex (GNPX) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TIPRANKS  ·  04-03
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Genprex (GNPX) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
Evaxion Biotech Advances AI-Driven Vaccine Development
TIPRANKS  ·  03-27
Evaxion Biotech Advances AI-Driven Vaccine Development
Evaxion Biotech Q4 EPS $(0.16) Beats $(1.60) Estimate, Sales $73.00K
Benzinga  ·  03-27
Evaxion Biotech Q4 EPS $(0.16) Beats $(1.60) Estimate, Sales $73.00K

Introduction

Company Name.
Evaxion Biotech A/S
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Issue price:
--